Expert neurologists discuss the impact of MS on the immune system and comment on the use of COVID-19 vaccines with MS treatment and the use of high efficacy therapies in MS.
EP. 1: Innate vs Adaptive Immunity in MS Management
Barry A. Hendin, MD, and Regina Berkovich, MD, PhD, provide an overview of the immune system, focusing on innate vs adaptive immunity, in the management of multiple sclerosis.
EP. 2: Innate and Adaptive Immunity and BTK Inhibitors for Multiple Sclerosis
Barry A. Hendin, MD, discusses innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).
EP. 3: Role of Inflammation in MS
Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.
EP. 4: Role of High Efficacy Therapy for MS
Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.
EP. 5: Use of High-Efficacy Therapy in MS in Clinical Practice
Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.
EP. 6: Considerations for Using High-Efficacy Therapy in MS
Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.
EP. 7: Updates From ACTRIMS 2022 for Relapsing MS
Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review clinical implications of real-world data on the use of cladribine and other DMTs in patients with relapsing MS that were presented at ACTRIMS 2022.
EP. 8: Treating Smoldering Inflammation in MS
Drs Barry A. Hendin and Regina Berkovich comment on the management and treatment of chronic smoldering inflammation with high efficacy therapies.
EP. 9: Guidance on COVID-19 Vaccines for Patients With MS
Barry A. Hendin, MD, reviews guidance on COVID-19 vaccines for patients with MS, including highlights from the AAN position statement.
EP. 10: Response to COVID-19 Vaccines in Patients Treated With High Efficacy DMTs
Dr Regina Berkovich evaluates the use of mRNA COVID-19 vaccines in patients treated with high efficacy disease-modifying therapies for MS.
EP. 11: VELOCE Study in Relapsing MS
Clinical implications from VELOCE, a phase 3b study examining the effect of ocrelizumab on immune responses in patients with relapsing MS.
EP. 12: Managing MS in the COVID-19 Era
Expert neurologists comment on the impact of COVID-19 on telemedicine and MS treatment selection.
EP. 13: Future of MS With BTK Inhibitors
Regina Berkovich, MD, PhD, and Barry A. Hendin, MD, review potential use of BTK inhibitors in the treatment of MS.
EP. 14: MS Diagnosis and Management Going Forward
Barry A. Hendin, MD; Regina Berkovich, MD, PhD; and Ahmed Z. Obeidat, MD, PhD, explore the role of biomarkers, precision medicine, and repair mechanisms to improve treatment of MS going forward.
EP. 15: Clinical Pearls for the Management of MS
Expert neurologists emphasize the importance of conversations around patient lifestyle, mental health, and comorbid conditions as keys to improve care for MS.
2 Commerce Drive Cranbury, NJ 08512